- Home
- A-Z Publications
- Current Topics in Medicinal Chemistry
- Previous Issues
- Volume 12, Issue 13, 2012
Current Topics in Medicinal Chemistry - Volume 12, Issue 13, 2012
Volume 12, Issue 13, 2012
-
-
From the Deepest Sea Shelf to the Uppermost Kitchen Cabinet Shelf: The Quest for Novel TNF-α Inhibitors
Authors: F. Folmer, M. Dicato and M. DiederichTNF-α was discovered more then 20 years ago as a cytokine implicated in a wide range of cell signaling pathways, many of which are known to lead to the activation of genes involved in inflammation and carcinogenesis. TNF-α is involved in the pathogenesis of many diseases, including Crohn’s disease, diabetes, septic shock, tumorigenesis, rheumatoid arthritis, psoriatic arthritis and inflammatory bowel disease. Multidis Read More
-
-
-
TNF-α Inhibitors with Anti-Oxidative Stress Activity from Natural Products
Authors: Jing Li, Huibin Zhang, Wenlong Huang, Hai Qian and Ying LiTumor necrosis factor-α (TNF-α) is a major cytokine involved in the inflammatory response. Elevated TNF-α expression has been found to be associated with the development of diabetes, septic shock, tumorigenesis, cardiovascular diseases, rheumatoid arthritis and inflammatory bowel disease. In the past decade, the success of anti-TNF-α biologics has valuated the importance of the blockade of TNF-α production in the Read More
-
-
-
Therapeutic Potential of Natural Products from Terrestrial Plants as TNF-α Antagonist
Authors: Praveen Kumar Verma, Manju Bala, Neeraj Kumar and Bikram SinghTumor necrosis factor-alpha (TNF-α) is a multifunctional cytokine produced by monocytes, macrophages, neutrophils, T-cells, mast cells, epithelial cells, osteoblasts and dendritic cells. It can regulate numerous cellular and biological processes such as immune function, cell differentiation, proliferation, apoptosis and energy metabolism. It is also involved in the pathogenesis of multiple chronic inflammatory or autoimmune Read More
-
-
-
Thalidomide: Chemistry, Therapeutic Potential and Oxidative Stress Induced Teratogenicity
Authors: Neeraj Kumar, Upendra Sharma, Chitra Singh and Bikram SinghThalidomide and its one analogue, lenalidomide (CC5103 or revlimid) are recently approved for the treatment of multiple myeloma. Multiple myeloma is characterized by an overproduction of malignant plasma cells in the bone marrow. The journey of thalidomide was started in 1956 when it was marketed as a non-barbiturate sedative agent. It was considered as a “wonder drug” that provided safe and sound sleep an Read More
-
-
-
TNF α Signaling Beholds Thalidomide Saga: A Review of Mechanistic Role of TNF-α Signaling Under Thalidomide
More LessTumor necrosis factor alpha (TNF-α) is a pleiotropic inflammatory cytokine. The cytokine possesses both growth stimulating properties and growth inhibitory processes, and it appears to have self regulatory properties as well. Agents like etanercept and infliximab showed beneficial effects against rheumatoid arthritis by modulationg TNF-α proteins, however, these agents are largely unable to penetrate the blood-brain barri Read More
-
Volumes & issues
-
Volume 25 (2025)
-
Volume 24 (2024)
-
Volume 23 (2023)
-
Volume 22 (2022)
-
Volume 21 (2021)
-
Volume 20 (2020)
-
Volume 19 (2019)
-
Volume 18 (2018)
-
Volume 17 (2017)
-
Volume 16 (2016)
-
Volume 15 (2015)
-
Volume 14 (2014)
-
Volume 13 (2013)
-
Volume 12 (2012)
-
Volume 11 (2011)
-
Volume 10 (2010)
-
Volume 9 (2009)
-
Volume 8 (2008)
-
Volume 7 (2007)
-
Volume 6 (2006)
-
Volume 5 (2005)
-
Volume 4 (2004)
-
Volume 3 (2003)
-
Volume 2 (2002)
-
Volume 1 (2001)
Most Read This Month
Article
content/journals/ctmc
Journal
10
5
false
en
